ZURA vs. PRTA, HRTX, AURA, TKNO, RCKT, AVTE, GLUE, PRME, OLMA, and AVIR
Should you be buying Zura Bio stock or one of its competitors? The main competitors of Zura Bio include Prothena (PRTA), Heron Therapeutics (HRTX), Aura Biosciences (AURA), Alpha Teknova (TKNO), Rocket Pharmaceuticals (RCKT), Aerovate Therapeutics (AVTE), Monte Rosa Therapeutics (GLUE), Prime Medicine (PRME), Olema Pharmaceuticals (OLMA), and Atea Pharmaceuticals (AVIR). These companies are all part of the "pharmaceutical products" industry.
Zura Bio vs. Its Competitors
Zura Bio (NASDAQ:ZURA) and Prothena (NASDAQ:PRTA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, dividends, profitability, valuation, risk and earnings.
Zura Bio has a net margin of 0.00% compared to Prothena's net margin of -79.94%. Prothena's return on equity of -21.61% beat Zura Bio's return on equity.
Zura Bio has higher earnings, but lower revenue than Prothena. Prothena is trading at a lower price-to-earnings ratio than Zura Bio, indicating that it is currently the more affordable of the two stocks.
61.1% of Zura Bio shares are held by institutional investors. Comparatively, 97.1% of Prothena shares are held by institutional investors. 14.2% of Zura Bio shares are held by insiders. Comparatively, 9.2% of Prothena shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Zura Bio has a beta of -0.1, suggesting that its share price is 110% less volatile than the S&P 500. Comparatively, Prothena has a beta of 0.01, suggesting that its share price is 99% less volatile than the S&P 500.
In the previous week, Zura Bio and Zura Bio both had 1 articles in the media. Zura Bio's average media sentiment score of 1.71 beat Prothena's score of 0.00 indicating that Zura Bio is being referred to more favorably in the media.
Zura Bio currently has a consensus price target of $14.33, indicating a potential upside of 1,161.74%. Prothena has a consensus price target of $31.50, indicating a potential upside of 386.86%. Given Zura Bio's stronger consensus rating and higher possible upside, analysts plainly believe Zura Bio is more favorable than Prothena.
Summary
Zura Bio beats Prothena on 10 of the 15 factors compared between the two stocks.
Get Zura Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for ZURA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ZURA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Zura Bio Competitors List
Related Companies and Tools
This page (NASDAQ:ZURA) was last updated on 7/4/2025 by MarketBeat.com Staff
